Obesity and hidradenitis suppurativa: targeting meta-inflammation for therapeutic gain

Dillon Mintoff; Rachel Agius; Farida Benhadou; Anupam Das; John W Frew; Nikolai P Pace

doi:10.1093/ced/llad182

Obesity and hidradenitis suppurativa: targeting meta-inflammation for therapeutic gain

Clin Exp Dermatol. 2023 Aug 25;48(9):984-990. doi: 10.1093/ced/llad182.

Authors

Dillon Mintoff^{1

2}, Rachel Agius^{3

4}, Farida Benhadou⁵, Anupam Das⁶, John W Frew^{7

8

9}, Nikolai P Pace^{4

10}

Affiliations

¹ Department of Dermatology.
² Department of Pathology, Faculty of Medicine and Surgery.
³ Diabetes and Endocrine Centre, Mater Dei Hospital, Msida, Malta.
⁴ Faculty of Medicine and Surgery.
⁵ Department of Dermatology, Hôpital Erasme, Universite Libre de Bruxelles, Bruxelles, Belgium.
⁶ Department of Dermatology, Venereology and Leprosy; KPC Medical College & Hospital, Kolkata, India.
⁷ Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.
⁸ Department of Dermatology, Liverpool Hospital, Sydney, NSW, Australia.
⁹ University of New South Wales, Sydney, NSW, Australia.
¹⁰ Centre for Molecular Medicine and Biobanking, University of Malta, Msida, Malta.

PMID: 37171791
DOI: 10.1093/ced/llad182

Abstract

Hidradenitis suppurativa (HS) is a chronic, inflammatory condition of the pilosebaceous unit. The typical patient with HS is characterized as someone with obesity, who smokes and who has nodules, abscesses and/or draining tunnels predominantly distributed in intertriginous skin. It has been established that lifestyle and genetic factors are the main pathophysiological drivers of HS. In this critical review, we explore the interrelatedness of meta-inflammation, obesity and HS and discuss if and how this relationship may be manipulated for a therapeutic end.

Publication types

Review

MeSH terms

Abscess
Hidradenitis Suppurativa* / drug therapy
Humans
Life Style
Obesity / complications